Author:
Bronsveld Inez,Mekus Frauke,Bijman Jan,Ballmann Manfred,de Jonge Hugo R.,Laabs Ulrike,Halley Dicky J.,Ellemunter Helmut,Mastella Gianni,Thomas Stephen,Veeze Henk J.,Tümmler Burkhard
Publisher
American Society for Clinical Investigation
Cited by
103 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years;Frontiers in Pharmacology;2023-05-30
2. Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy;Frontiers in Pharmacology;2023-01-27
3. IL1B gene variants, but not TNF, CXCL8, IL6 and IL10, modify the course of cystic fibrosis in Polish patients.;F1000Research;2022-11-22
4. IL1B gene variants, but not TNF, CXCL8, IL6 and IL10, modify the course of cystic fibrosis in Polish patients.;F1000Research;2022-05-23
5. IL1B gene variants, but not TNF, CXCL8, IL6 and IL10, modify the course of cystic fibrosis in Polish patients.;F1000Research;2022-03-31